MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchCrypto SummaryFAQAbout
Medical Laboratories Stocks$69.93
0.64%4:00PM 01/26/2023
The list of companies include BIOC-Biocept Inc, CDNA-Caredx Inc, CELC-Celcuity Inc, NTRA-Natera Inc, NVTA-Invitae Corp, OPGN-Opgen Inc, PSNL-Personalis Inc, VCYT-Veracyte Inc, WST-West Pharmaceutical Services, Inc.
Latest intraday update before market close @ 19:45:42 PM 01/27/2023
Summary :
Average return is up 1.1%
Median return is up 0.6%
6 out of 9 stocks are up (limited to those with intraday pricing feeds).

Aggregated price index

Aggregated price index with volume information

Summary:

  • Medical Laboratories stocks up 0.6% on average while median return up 1.1% in a day
  • Medical Laboratories stocks up 2.8% on average while median return up 5.5% in a week
  • Medical Laboratories stocks up 22.7% on average while median return up 15.1% in a month
  • When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.

Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.

Related Stocks

Click on + to show price series and click on ticker for stock detail page

Ticker
1 Day Return
1 Week Return
1 Month Return
PE Ratio
PE/G
P/B (mrq)
P/S (ttm)
Earning Growth
MarketCap
Short %
Held By Institutions %
RSI
Price Pattern
Resist Support
Days Since Channel Change
Channel Slope (daily rate %)
GTH6.0%
5.1%
33.9%
4.26107.4M22%63/\132-0.3%
WST3.7%
6.0%
14.9%
32.71.7514.2111.18103%20B2%95%69/\Above resistance159-0.2%
NTRA1.8%
7.7%
2.9%
-7.5424.1520.144.2B8%101%57/-\/1590.2%
VCYT1.2%
8.9%
6.0%
2.5920.481.9B7%106%53/\/1590.1%
CDNA1.1%
11.0%
35.0%
15.769.7620.86815.4M11%101%68/\159-0.4%
CELC-1.4%
-3.6%
-17.9%
-0.549.10229M7%25%46\/1300.2%
PSNL-3.4%
1.8%
15.4%
-10.796.8913.46103.9M9%87%47/\159-0.4%
NVTA-3.9%
1.7%
35.9%
-0.17-1.92.7320.54597.5M16%82%54/\159-0.2%

* P/E and MarketCap are refreshed daily using IEX Cloud service. P/B, P/S, PEG, growth, short%, HelbyInstitute are refreshed weekly using Yahoo feeds. For latest stock stats please visit Yahoo Finance.

* Price Patter: / is upward trend, \ is downward trend, - is sideway. Click on the ticker to go to stock page to see Bayesian Trend model plot of the time series.

* Channel and change points are derived from Bayesian Trend model, where the channel slope is the growth rate while change points are those the model partition the time series.

Related ETFs (click on ticker for stock detail page)

leak data

  • 1M winners are : Winners for past month are $NVTA 35.9%, $CDNA 35.0%, $GTH 33.9%, $PSNL 15.4%
  • 1M losers are : Losers for past month are $CELC -17.9%
  • 1W winners are : Winners for past week are $CDNA 11.0%, $VCYT 8.9%, $NTRA 7.7%, $WST 6.0%
  • 1W losers are : Losers for past week are $CELC -3.6%
Pick two stocks to compare:

Correlation Analysis

Index correlation analysis

Correlation for the past month is 28.4%, for the past 3 months is 17.3%

In the past month for a 5 days rolling window, the highest corrrelation is 48.4%, the lowest correlation is -9.3%, the latest correlation is 37.4%

When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.

Among pairwise correlation, the highest correlation is 86.3% between CDNA and VCYT

The lowest correlation is -33.6% between ANPC and PSNL

Stock news

    01/26/2023CDNA
    CareDx (NASDAQ:CDNA) delivers shareholders splendid 20% CAGR over 5 years, surging 9.8% in the last week alone

    CareDx, Inc ( NASDAQ:CDNA ) shareholders might be concerned after seeing the share price drop 24% in the last quarter...

    01/26/2023CDNA
    JACC Publication Guides Use of CareDx’s HeartCare Transplant Rejection Surveillance in Clinical Practice

    BRISBANE, Calif., January 26, 2023--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Journal of the American College of Cardiology (JACC): Heart Failure has published a detailed guide1 to help clinicians transition from routine invasive endomyocardial biopsy (EMB) to a less invasive acute rejection monito

    01/20/2023ANPC
    AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request A Hearing

    New York, NY, Jan. 20, 2023 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (the “Company”) (Nasdaq: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection announced that, on January 13, 2023, it received a Staff determination letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company of the Staff’s determination to delist the Company’s securities f

    01/19/2023PSNL
    Fremont cancer test business Personalis to cut staff by one-third

    Cancer test business Personalis Inc. is cutting a third of its staff in a move that's estimated to affect more than 100 workers. It said the layoffs are being done to "reduce operating costs and improve operating efficiency." Personalis didn't specify the number of jobs to be cut but in an annual report last year it said it employed 326 people at the end of 2021.

    01/19/2023PSNL
    Cancer Genomics-Focused Personalis To Reduce Nearly One-Third Of Its Workforce

    Personalis Inc (NASDAQ: PSNL) approved a reduction in the company's workforce by up to approximately 30% to reduce operating costs and improve operating efficiency. The reduction in workforce is expected to be completed on March 20, 2023. The company estimates that it will incur charges of approximately $3 million for severance payments and employee benefits, primarily in the first quarter of 2023. The company estimates that the reduction in workforce will save approximately $17 million, net in

    01/18/2023NTRA
    Raymond James Upgrades Natera & Myriad Genetics, While Downgrading This Stock

    Raymond James upgraded Natera Inc (NASDAQ: NTRA) to Outperform from Market Perform and a price target of $58 on a catalyst-rich setup for 2023 across segments, but most interestingly, in the molecular residual disease arena. The analyst expects additional coverage and potential guideline inclusion, at least for colorectal cancer, with women's health having its catalysts. The analyst also upgraded Myriad Genetics Inc (NASDAQ: MYGN) to Outperform from Market Perform and a price target of $25. Raym

    01/18/2023GTH
    Genetron Health Regains Compliance With Nasdaq Minimum Bid Price Requirement

    BEIJING, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that the Company had received a notification letter (“Compliance Notice”) from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”), dated Jan

    01/11/2023WST
    Reasons to Retain West Pharmaceutical (WST) in Your Portfolio

    West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.

    01/11/2023CDNA
    CareDx Fosters Transplant Innovation as Distinguished Founder’s Circle Sponsor for the 23rd Annual American Society of Transplant Surgeons State of the Art Winter Symposium

    BRISBANE, Calif., January 11, 2023--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers -- today announced its leading participation and top spot, for the fourth consecutive year, as a Distinguished Founder’s Circle Sponsor for the 23rd Annual ASTS (American Society of Transplant Surgeons) State of the Art Winter Symposium

    01/9/2023CDNA
    CareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2022

    BRISBANE, Calif., January 09, 2023--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported preliminary financial results for the fourth quarter and full year ended December 31, 2022.